Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 154

1.

High-dose riboflavin treatment is efficacious in migraine prophylaxis: an open study in a tertiary care centre.

Boehnke C, Reuter U, Flach U, Schuh-Hofer S, Einhäupl KM, Arnold G.

Eur J Neurol. 2004 Jul;11(7):475-7.

PMID:
15257686
[PubMed - indexed for MEDLINE]
2.

Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.

Cady R, Schreiber C.

Headache. 2008 Jun;48(6):900-13. Epub 2007 Nov 28.

PMID:
18047501
[PubMed - indexed for MEDLINE]
3.

Botulinum toxin type a prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study.

Aurora SK, Gawel M, Brandes JL, Pokta S, Vandenburgh AM; BOTOX North American Episodic Migraine Study Group.

Headache. 2007 Apr;47(4):486-99.

PMID:
17445098
[PubMed - indexed for MEDLINE]
4.

Botulinum toxin type a for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study.

Dodick DW, Mauskop A, Elkind AH, DeGryse R, Brin MF, Silberstein SD; BOTOX CDH Study Group.

Headache. 2005 Apr;45(4):315-24.

PMID:
15836567
[PubMed - indexed for MEDLINE]
5.

Duration of migraine is a predictor for response to botulinum toxin type A.

Eross EJ, Gladstone JP, Lewis S, Rogers R, Dodick DW.

Headache. 2005 Apr;45(4):308-14.

PMID:
15836566
[PubMed - indexed for MEDLINE]
6.

Effectiveness of high-dose riboflavin in migraine prophylaxis. A randomized controlled trial.

Schoenen J, Jacquy J, Lenaerts M.

Neurology. 1998 Feb;50(2):466-70.

PMID:
9484373
[PubMed - indexed for MEDLINE]
7.

A combination of riboflavin, magnesium, and feverfew for migraine prophylaxis: a randomized trial.

Maizels M, Blumenfeld A, Burchette R.

Headache. 2004 Oct;44(9):885-90.

PMID:
15447697
[PubMed - indexed for MEDLINE]
8.

Botulinum toxin type A for migraine prophylaxis in the Japanese population: an open-label prospective trial.

Suzuki K, Iizuka T, Sakai F.

Intern Med. 2007;46(13):959-63. Epub 2007 Jul 2.

PMID:
17603233
[PubMed - indexed for MEDLINE]
Free Article
9.

Correlation of increase in phosphene threshold with reduction of migraine frequency: observation of levetiracetam-treated subjects.

Young W, Shaw J, Bloom M, Gebeline-Myers C.

Headache. 2008 Nov-Dec;48(10):1490-8. doi: 10.1111/j.1526-4610.2008.01292.x.

PMID:
19076647
[PubMed - indexed for MEDLINE]
10.

Efficacy of coenzyme Q10 in migraine prophylaxis: a randomized controlled trial.

Sándor PS, Di Clemente L, Coppola G, Saenger U, Fumal A, Magis D, Seidel L, Agosti RM, Schoenen J.

Neurology. 2005 Feb 22;64(4):713-5.

PMID:
15728298
[PubMed - indexed for MEDLINE]
11.

Open-label trial of cinnarizine in migraine prophylaxis.

Togha M, Ashrafian H, Tajik P.

Headache. 2006 Mar;46(3):498-502.

PMID:
16618269
[PubMed - indexed for MEDLINE]
12.

Headache prevention outcome and body mass index.

Bigal ME, Gironda M, Tepper SJ, Feleppa M, Rapoport AM, Sheftell FD, Lipton RB.

Cephalalgia. 2006 Apr;26(4):445-50.

PMID:
16556246
[PubMed - indexed for MEDLINE]
13.

The efficacy of divalproex sodium in the prophylactic treatment of children with migraine.

Caruso JM, Brown WD, Exil G, Gascon GG.

Headache. 2000 Sep;40(8):672-6.

PMID:
10971664
[PubMed - indexed for MEDLINE]
14.

Zonisamide for migraine prophylaxis in refractory patients.

Ashkenazi A, Benlifer A, Korenblit J, Silberstein SD.

Cephalalgia. 2006 Oct;26(10):1199-202.

PMID:
16961786
[PubMed - indexed for MEDLINE]
15.

The impact of intensive patient education on clinical outcome in a clinic-based migraine population.

Rothrock JF, Parada VA, Sims C, Key K, Walters NS, Zweifler RM.

Headache. 2006 May;46(5):726-31. Erratum in: Headache. 2006 Jul-Aug;46(7):1227.

PMID:
16643574
[PubMed - indexed for MEDLINE]
16.

Divalproex sodium extended-release for the prophylaxis of migraine headache in adolescents: results of a stand-alone, long-term open-label safety study.

Apostol G, Lewis DW, Laforet GA, Robieson WZ, Fugate JM, Abi-Saab WM, Saltarelli MD.

Headache. 2009 Jan;49(1):45-53. doi: 10.1111/j.1526-4610.2008.01279.x. Epub 2008 Nov 14.

PMID:
19040679
[PubMed - indexed for MEDLINE]
17.

Open-label, long-term tolerability of naratriptan for short-term prevention of menstrually related migraine.

Brandes JL, Smith T, Diamond M, Ames MH.

Headache. 2007 Jun;47(6):886-94.

PMID:
17578540
[PubMed - indexed for MEDLINE]
18.

Evaluation of carisbamate for the treatment of migraine in a randomized, double-blind trial.

Cady RK, Mathew N, Diener HC, Hu P, Haas M, Novak GP; Study Group.

Headache. 2009 Feb;49(2):216-26. doi: 10.1111/j.1526-4610.2008.01326.x.

PMID:
19222595
[PubMed - indexed for MEDLINE]
19.

Naratriptan in the preventive treatment of refractory transformed migraine: a prospective pilot study.

Sheftell FD, Rapoport AM, Tepper SJ, Bigal ME.

Headache. 2005 Nov-Dec;45(10):1400-6.

PMID:
16324173
[PubMed - indexed for MEDLINE]
20.

Acupuncture in migraine prevention: a randomized sham controlled study with 6-months posttreatment follow-up.

Alecrim-Andrade J, Maciel-Júnior JA, Carnè X, Severino Vasconcelos GM, Correa-Filho HR.

Clin J Pain. 2008 Feb;24(2):98-105. doi: 10.1097/AJP.0b013e3181590d66.

PMID:
18209514
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk